We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Professor Plevin and Dr Margaret Cunningham will investigate an enzyme that might play a role in osteosarcoma development, and see whether this could form the basis of a new type of treatment.
Dr Olivier Pardo will investigate how osteosarcoma cells which escape into the bloodstream survive to spread elsewhere in the body.
Dr Jess Morgan at the University of York will review the latest experimental treatments for hard-to-treat neuroblastoma to help with decision-making.
Dr Jess Morgan at the University of York hopes to understand what we already know about using portable chemotherapy pumps for children with cancer.
Dr Lucia Cottone at University College London hopes to understand how osteosarcoma cells become resistant to chemotherapy, which has a big impact on patient survival.
Dr Olivier Pardo at Imperial College London aims to find out how osteosarcoma cells survive the bloodstream and spread elsewhere in the body.
It is particularly difficult to treat some groups of childhood cancer patients, especially infants in their first weeks of life. This application is to fund this rapidly developing research programme for two years, involving the treatment of 150-200.
Evaluating a novel protein methyltransferase inhibitor for poor-prognosis rhabdomyosarcoma therapy
Diffuse midline glioma is a devastating brain tumour, affecting primarily young children. There’s currently no cure for this disease and treatment options are limited. This is mainly because this type of tumour is well-protected from drugs by the ‘blood-brain barrier’. This barrier physically blocks all medications from entering the brain. Our group has developed new methods of bypassing this barrier using focused ultrasound.
